Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $243,781 - $355,514
67,717 Added 40.45%
235,137 $1.03 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $590,880 - $1.14 Million
137,414 Added 457.96%
167,420 $745,000
Q4 2022

Feb 14, 2023

BUY
$5.66 - $8.42 $169,833 - $252,650
30,006 New
30,006 $253,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $91.5M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.